01
State of the Field
Neurotechnology does three things: it reads signals from the nervous system, stimulates it, or links the two in a feedback loop.
The short version: neurotech already works in people. Users can move cursors, type, reduce tremor, and recover pieces of vision[1][2][3].
What is missing is a system people can rely on for years. The hard problems now are durability, calibration, surgery, reimbursement, maintenance, and trust.
02
How Neurotech Actually Works
Most systems can be understood in three verbs: read, write, and close the loop.
03
What Matters
04
Interface Modalities
Getting closer to neurons usually gives a cleaner signal. It also means more surgery, more tissue contact, and more ways for the body to push back.
| Approach | What it touches | Main strength | Main weakness | Representative names |
|---|
05
Field Landscape
Compare companies by interface path, first job, and evidence. Read left to right as the procedure gets harder, then open a company for the sources behind it.
Who else matters
The field is bigger than startups
Startups get the headlines. Device makers, labs, hospitals, regulators, and payers decide what can actually reach patients.
06
Where Neurotech Works First
The best first products solve one painful problem and make the result easy to measure.
07
What the Evidence Shows
The paper trail is strongest in closed-loop therapy and communication, and thinnest in broad consumer thought decoding.
08
Timeline
09
What Is Still Hard
10
What Comes Next
11
What Success Looks Like
A neural interface should be judged by what it gives the user—not by what it can extract.
12
Sources
The company pages, papers, and reporting used in this guide.